Study identification

EU PAS number

EUPAS9592

Study ID

13643

Official title and acronym

Effect of Incretin Analogues and Dipeptidyl-peptidase-IV inhibitors on colorectal cancer risk

DARWIN EU® study

No

Study countries

United States

Study description

This will be a retrospective cohort study using a new-user active comparator design on Medicare Part A, B and D claims data from 2007-2012. The study population consists of Medicare enrollees initiating incretin-based drugs (GLP-1ra or DPP-4i) or other antidiabetic drugs (TZDs, sulfonylureas or long-acting insulins). New users of incretin-based drugs and other antidiabetic drugs will be compared with respect to incidence of colorectal cancer (primary outcome) and incidence of colorectal cancer combined with benign colorectaltumors (secondary outcome) adjusted for baseline information collected prior to drug initiation.

Study status

Finalised
Research institutions and networks

Institutions

Gillings School of Public Health

Contact details

Til Stürmer

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

Unfunded
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable